en
Scientific article
English

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study Group

Published inClinical infectious diseases, vol. 52, no. 10, p. 1257-1266
Publication date2011-05
Abstract

Background: Triple nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the World Health Organization as first-line regimen in treatment-naïve HIV-2-infected patients. However, ritonavir-boosted protease inhibitor (PI/r)-containing regimens are frequently prescribed. In the absence of previous randomized trials, we retrospectively compared these regimens in observational cohorts.

Methods: HIV-2-infected patients from 7 European cohorts who started triple NRTI or PI/r since January 1998 were included. Piecewise linear models were used to estimate CD4 cell count and plasma HIV-2 RNA level slopes, differentiating an early phase (until end of month 3) and a second phase (months 4-12). On-treatment analyses censored data at major treatment modification and systematically at month 12.

Results: Forty-four patients started triple NRTI therapy and 126 started PI/r therapy. Overall, the median CD4 cell count was 191 cells/mm(3) and the median plasma HIV-2 RNA level was ≥2.7 log(10) copies/ml in 61% of the patients at combination antiretroviral therapy (cART) initiation; the median duration of the first cART was 20 months, not differing between groups. PI/r regimens were associated with better CD4 cell count and HIV-2 RNA level outcomes, compared with NRTI regimens. Estimated CD4 cell count slopes were +6 and +12 cells/mm(3)/month during the early phase (P = .22), and -60 cells/mm(3)/year versus +76 cells/mm(3)/year during the second phase (P = .002), for triple NRTI and PI/r, respectively. Estimated mean HIV-2 RNA levels at month 12 in patients with detectable viremia at cART initiation were 4.0 and 2.2 log(10) copies/ml, respectively (P = .005).

Conclusions: In this observational study, PI/r-containing regimens showed superior efficacy over triple NRTI regimens as first-line therapy in HIV-2-infected patients.

eng
Keywords
  • Adult
  • Anti-HIV Agents / administration & dosage
  • CD4 Lymphocyte Count
  • Europe
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease Inhibitors / administration & dosage
  • HIV-2 / isolation & purification
  • Humans
  • RNA, Viral / blood
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Ritonavir / administration & dosage
  • Treatment Outcome
  • Viral Load
Research group
Citation (ISO format)
BENARD, Antoine et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study Group. In: Clinical infectious diseases, 2011, vol. 52, n° 10, p. 1257–1266. doi: 10.1093/cid/cir123
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1058-4838
25views
0downloads

Technical informations

Creation02/07/2023 8:40:05 AM
First validation11/20/2023 10:57:37 AM
Update time11/20/2023 10:57:37 AM
Status update11/20/2023 10:57:37 AM
Last indexation05/06/2024 5:25:05 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack